SIRT6 and non-small cell lung carcinoma: Interestingly, studies revealed that SIRT6 increases glycolysis through the HIF-1α/HK2 signaling axis in drug-resistant cells and diminishes sensitivity to erlotinib in NSCLC cells (Figure 5 F, H)211.